Approval · Notice of Compliance 17080 · 2015
EPERZAN: Notice of Compliance 17080
Issued July 15, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17080
- Date
- July 15, 2015
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Human glucagon-like peptide-1 (glp-1) receptor agonist
Products in this notice
Medicinal ingredients
- ALBIGLUTIDE 30 MG per 0.5ML
- ALBIGLUTIDE 50 MG per 0.5ML